Table 2.
Results of the association analysis between ABO blood group, PDAC susceptibility loci analysed individually and combined in a PGS, and the risk of IPMN progression.
| Number of subjects (progressed/non-progressed) |
No WFs at diagnosis | All IPMNs | ||||
|---|---|---|---|---|---|---|
| 298 (91/207) | - | 354 (234/120) | - | |||
| Blood group | HR (95% CI) | p | HR (95% CI) | p | ||
| Non-O blood group vs. O group | 0.89 (0.59–1.35) | 0.581 | 0.97 (0.67–1.39) | 0.857 | ||
| A blood group vs. O group | 0.93 (0.60–1.45) | 0.761 | 0.97 (0.66–1.43) | 0.896 | ||
| AB blood group vs. O group | 1.24 (0.49–3.15) | 0.646 | 1.22 (0.52–2.85) | 0.642 | ||
| B groups vs. O group | 0.54 (0.21–1.37) | 0.193 | 0.80 (0.38–1.68) | 0.556 | ||
| Genetic variant | RA | EA | HR (95% CI) | p | HR (95% CI) | p |
| rs7046076 | t | c | 0.89 (0.64–1.26) | 0.515 | 0.96 (0.71–1.29) | 0.781 |
| rs2035875 | g | a | 1.07 (0.77–1.47) | 0.694 | 1.11 (0.83–1.47) | 0.479 |
| rs13303010 | a | g | 1.1 (0.73–1.67) | 0.639 | 1.12 (0.77–1.61) | 0.555 |
| rs2736100 | a | c | 0.94 (0.70–1.26) | 0.689 | 0.97 (0.75–1.25) | 0.821 |
| rs351365 | c | t | 0.87 (0.60–1.26) | 0.459 | 0.85 (0.62–1.18) | 0.345 |
| rs2816938 | a | t | 0.86 (0.61–1.21) | 0.388 | 0.82 (0.60–1.10) | 0.185 |
| rs3790844 | a | g | 0.97 (0.66–1.45) | 0.901 | 0.98 (0.68–1.40) | 0.899 |
| rs1486134 | t | g | 0.77 (0.54–1.10) | 0.152 | 0.75 (0.54–1.04) | 0.082 |
| rs9854771 | g | a | 0.84 (0.61–1.16) | 0.292 | 0.92 (0.71–1.20) | 0.561 |
| rs2853677 | a | g | 0.99 (0.74–1.34) | 0.964 | 1.05 (0.82–1.36) | 0.681 |
| rs2736098 | t | c | 0.92 (0.66–1.29) | 0.641 | 0.96 (0.72–1.29) | 0.79 |
| rs35226131 | c | t | 0.63 (0.31–1.28) | 0.200 | 0.72 (0.44–1.20) | 0.214 |
| rs401681 | c | t | 1.10 (0.81–1.49) | 0.561 | 1.11 (0.86–1.44) | 0.422 |
| rs17688601 | c | a | 0.94 (0.69–1.28) | 0.697 | 0.94 (0.72–1.23) | 0.671 |
| rs73328514 | a | t | 0.95 (0.59–1.53) | 0.840 | 1.03 (0.67–1.56) | 0.905 |
| rs6971499 | t | c | 0.95 (0.57–1.58) | 0.851 | 0.95 (0.61–1.48) | 0.835 |
| rs172310 | c | a | 1.15 (0.85–1.57) | 0.369 | 1.19 (0.92–1.55) | 0.189 |
| rs2941471 | a | g | 0.98 (0.72–1.34) | 0.914 | 0.92 (0.70–1.21) | 0.548 |
| rs10094872 | t | a | 1.30 (0.92–1.85) | 0.141 | 1.39 (1.02–1.89) | 0.035 |
| rs1561927 | t | c | 0.89 (0.62–1.29) | 0.543 | 1.03 (0.75–1.42) | 0.846 |
| rs10991043 | t | c | 0.98 (0.72–1.33) | 0.874 | 1.05 (0.80–1.37) | 0.739 |
| rs7310409 | g | a | 0.94 (0.69–1.29) | 0.716 | 1.02 (0.78–1.33) | 0.895 |
| rs9581943 | g | a | 1.04 (0.79–1.36) | 0.794 | 0.97 (0.77–1.24) | 0.829 |
| rs9543325 | t | c | 1.19 (0.86–1.64) | 0.298 | 1.13 (0.86–1.49) | 0.382 |
| rs8028529 | t | c | 0.87 (0.56–1.35) | 0.523 | 0.84 (0.57–1.24) | 0.385 |
| rs7190458 | g | a | 0.53 (0.21–1.33) | 0.175 | 0.69 (0.34–1.40) | 0.305 |
| rs4795218 | g | a | 0.91 (0.63–1.32) | 0.624 | 1.05 (0.76–1.44) | 0.779 |
| rs11655237 | c | t | 0.82 (0.50–1.35) | 0.435 | 0.88 (0.58–1.33) | 0.539 |
| rs1517037 | c | t | 1.54 (1.05–2.25) | 0.027 | 1.23 (0.89–1.70) | 0.209 |
| rs16986825 | c | t | 0.81 (0.54–1.21) | 0.299 | 1.04 (0.75–1.42) | 0.829 |
| rs8176746 | c | a | 0.69 (0.36–1.34) | 0.272 | 0.88 (0.50–1.54) | 0.652 |
| rs505922 | t | c | 0.98 (0.71–1.34) | 0.882 | 0.98 (0.74–1.28) | 0.856 |
| PGS | ||||||
| 2nd vs. 1st quintile | 1.25 (0.67–2.31) | 0.480 | 1.29 (0.74–2.23) | 0.366 | ||
| 3rd vs. 1st quintile | 1.50 (0.79–2.85) | 0.219 | 1.38 (0.78–2.44) | 0.271 | ||
| 4th vs. 1st quintile | 1.04 (0.56–1.94) | 0.902 | 1.01 (0.56–1.82) | 0.977 | ||
| 5th vs. 1st quintile | 0.90 (0.41–2.00) | 0.802 | 1.18 (0.66–2.09) | 0.579 | ||
All the analyses were adjusted by sex and age.
PGS, polygenic risk score; RA, reference allele; EA, effect allele; PDAC, pancreatic ductal adenocarcinoma; PGS, polygenic score; IPMN, intraductal papillary mucinous neoplasm; WFs, worrisome features.